Pre-workout Supplement, Arrhythmias and Exercise Stress Test
Can a Pre-workout Supplement Cause Arrhythmias During Physical Exercise in Young Physically Active Individuals? A Randomized, Double-blind, Placebo-controlled Study
Pre-workout supplements are widely used by physically active individuals to enhance exercise performance. These products typically contain stimulant substances such as caffeine, beta-alanine, arginine, and tyrosine, which act on the cardiovascular and central nervous systems. Although their ergogenic effects are well established, their safety profile - particularly regarding cardiac arrhythmias during exercise - has not been thoroughly investigated.
This study aimed to evaluate whether the acute ingestion of a commercially available multi-ingredient pre-workout supplement (V-FORT® ULTRA, Vitafor, Brazil) could trigger cardiac arrhythmias during a treadmill exercise stress test in young, physically active adults. A randomized, double-blind, placebo-controlled crossover design was used. Participants underwent two exercise stress tests separated by 3 to 10 days: a familiarization test (Day 1) and an intervention test (Day 2), in which they received either the pre-workout supplement or a placebo beverage. Neither the participants nor the research team conducting the test were aware of the allocated intervention until after test completion.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants were recruited via social media and screened for eligibility using the International Physical Activity Questionnaire (IPAQ). Only individuals meeting the criteria for physical activity (≥150 minutes/week of moderate-intensity or ≥75 minutes/week of vigorous-intensity exercise) and with prior experience using pre-workout supplements were enrolled.
On Day 1, all participants underwent a familiarization treadmill exercise stress test. Those presenting cardiac arrhythmias at baseline were excluded from the study.
On Day 2 (3 to 10 days later), participants were randomized in a 1:1 ratio to receive either the active supplement (V-FORT® ULTRA: 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, vitamins and minerals; 8 kcal per 8 g sachet) or a placebo (Tang® powdered juice: carbohydrates, sodium, vitamin C, and vitamin D; no stimulant substances). The beverage was prepared by the study coordinator in a separate room and consumed by the participant up to 3 hours before the exercise stress test. Both tests were performed at the same time of day for each participant.
The primary outcome was the occurrence of cardiac arrhythmias during the exercise stress test and the 6-minute post-exercise recovery phase, assessed by continuous 12-lead ECG. Secondary outcomes included adverse effects (tachycardia, paraesthesia) and exercise stress test duration.
Statistical analysis included descriptive statistics, normality testing (Shapiro-Wilk), paired comparisons (paired t-test or Wilcoxon signed-rank test for continuous variables; McNemar test for categorical variables), and logistic regression for confounder adjustment. IBM SPSS software was used for all analyses.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo
-
São Paulo, São Paulo, Brazil, 05021-010
- Pro-Coracao
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age 18 to 30 years Both sexes Physically active, defined as engaging in at least 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity per week, assessed by the International Physical Activity Questionnaire (IPAQ) Prior experience with pre-workout supplements (at least one previous use of any stimulant-based pre-workout supplement) No cardiac arrhythmias identified during the familiarization exercise stress test (Day 1)
Exclusion Criteria:
Presence of cardiac arrhythmias identified during the familiarization exercise stress test (Day 1) Physical inactivity (below the minimum physical activity thresholds on IPAQ) No prior use of any pre-workout or stimulant supplement Use of medications that may interfere with cardiovascular responses to exercise or supplementation Presence of known cardiovascular, metabolic, or musculoskeletal conditions that contraindicate exercise testing Orthopaedic limitations precluding treadmill exercise
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pre-Workout Supplement
Participants received a single dose of V-FORT® ULTRA (Vitafor, Brazil), a multi-ingredient pre-workout supplement containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. The beverage was consumed up to 3 hours before the treadmill exercise stress test. |
Single dose of containing 200 mg caffeine, 2,000 mg beta-alanine, 1,000 mg arginine, 600 mg tyrosine, 300 mg phenylalanine, 415 mg carnitine, 1.9 g carbohydrate, vitamins (C, E, B6, B12) and minerals (sodium, magnesium, zinc); 8 kcal per 8 g sachet. Consumed up to 3 hours before the treadmill exercise stress test. |
|
Placebo Comparator: Placebo
Participants received a single dose of Tang® powdered juice (placebo), containing 2.6 g carbohydrate, 2.4 g sugars, 22 mg sodium, 1.1 mg zinc, 23 mg vitamin C, and 2.5 mcg vitamin D, with no stimulant substances. The beverage was prepared to be visually and organoleptically indistinguishable from the active supplement and was consumed up to 3 hours before the treadmill exercise stress test. |
Juice |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Cardiac Arrhythmias During the Exercise Stress Test
Time Frame: During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)
|
Presence or absence of cardiac arrhythmias identified on continuous 12-lead ECG during the treadmill exercise stress test and the 6-minute post-exercise recovery phase, compared between the pre-workout supplement and placebo conditions. |
During the treadmill exercise stress test and throughout the 6-minute post-exercise recovery phase (approximately 30 to 60 minutes per session, on Day 2)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Haemodynamic Responses During the Exercise Stress Test
Time Frame: At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2
|
Blood pressure (systolic and diastolic) and heart rate measured at rest, at the end of each exercise stage, at peak effort, and during the post-exercise recovery phase (minutes 1, 2, 4, and 6), compared between the pre-workout supplement and placebo conditions. |
At rest, during each stage of the treadmill exercise stress test, at peak effort, and during the 6-minute post-exercise recovery phase on Day 2
|
|
Exercise Stress Test Duration
Time Frame: Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days
|
Total duration of the treadmill exercise stress test in minutes, compared between the pre-workout supplement and placebo conditions (Day 2), and between the familiarization test (Day 1) and the intervention test (Day 2) within the same participant. |
Day 1 (familiarization test) and Day 2 (intervention test), separated by 3 to 10 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 8.071.338
- 92811525.4.0000.0068 (Other Identifier: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.